Date: 2011-09-08
Type of information: R&D agreement
Compound: antibody technology
Company: Sucampo Pharmaceuticals (USA) Numab AG (Switzerland)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: Sucampo Pharmaceuticals and Numab AG have entered into a research and development collaboration that provides Sucampo with access to Numab's proprietary technology for the discovery of high-affinity antibodies against certain selected targets. Numab’s antibody has been designed to approach complex integral membrane proteins such as GPCRs or ion channels. Sucampo will have exclusive commercial rights to any biologic products successfully developed and commercialized in the course of the collaboration.
Sucampo may name up to four targets against which Numab will use their proprietary technology to discover high-affinity antibodies and to develop these to an IND-ready stage. Numab is eligible for FTE-based payments and discovery success-dependent fees. If a biologic is successfully developed, Numab and Sucampo may enter into a license arrangement in which Numab will be entitled to clinical development milestone payments and increasing tiered royalties on net sales. Sucampo will be responsible for clinical development and will retain all commercial rights to any resulting biologic product.
Financial terms: Under the terms of the agreement, Sucampo will provide Numab with up to 5,000,000 Swiss francs as collateral for a loan to Numab from a third party.
Latest news:
